Dapagliflozin Reduces Risk for Kidney Events in IgA Nephropathy
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
Diabetic Nephropathy
Albuminuria Reduction Greater With SGLT2 Inhibitor, ERA Combo
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.
Finerenone Gets Priority Review for Diabetic Kidney Disease
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Finerenone NDA Submitted for Diabetic Kidney Disease
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
Finerenone Slows CKD Progression in Diabetic Kidney Disease
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.
Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
Finerenone Found to Delay Progression of Diabetic Kidney Disease
Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.
